Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention
This is intended to facilitate the development and expedite the review of drugs that address serious or life-threatening medical conditions.
-
ViiV Healthcare announces results of the PROgress study demonstrating that the inclusion of patient reported outcomes into clinical practice can improve HIV care
ViiV Healthcare announces results of the PROgress study
-
GSK awards Greater Philadelphia nonprofits making a powerful IMPACT on health outcomes now more than ever
Ten local nonprofits were awarded $40,000 each in recognition of their outstanding contributions to a healthier Philadelphia region.
-
GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age
The results of the TEACH study were presented during the American Society of Tropical Medicine & Hygiene 2020 virtual annual meeting.
-
GSK starts phase 3 study of RSV maternal candidate vaccine
RSV is a leading cause of respiratory infections such as bronchiolitis and viral pneumonia in infants.
-
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
If approved, Nucala would be the only treatment approved in the US for use in four eosinophil-driven diseases.
-
GSK Consumer Healthcare Partners with Direct Relief to Donate $1 Million to Support Frontline Healthcare Workers
GSK donates on behalf of consumers to make sure healthcare workers have the supplies they need as the COVID-19 pandemic continues
-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine programme to improve immune response in the elderly
Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
-
Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19
Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19
-
FDA approves GSK’s BENLYSTA as the first medicine for adult patients with active lupus nephritis in the US
Approval builds on nearly 10 years of experience in lupus
-
Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
Second monoclonal antibody from Vir-GSK collaboration to be investigated as a potential COVID-19 treatment.
-
GSK presents positive efficacy data of dostarlimab in mismatch repair-deficient (dMMR) solid cancers at ASCO Gastrointestinal Cancers Symposium
Data from GARNET cohort F shows a 38.7% objective response rate with dostarlimab in patients with dMMR advanced solid cancers
-
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
ViiV Healthcare announces FDA approval of Cabenuva, the first & only complete long-acting regimen for HIV treatment
-
GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases
Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world.
-
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19.
-
GSK, PATH, and Bharat Biotech sign product transfer agreement to help ensure long-term supply of RTS,S/AS01E malaria vaccine
The agreement recognises the track record and expertise of BBIL in developing and supplying vaccines against infectious diseases.
-
GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER
Strong growth of new and specialty products; on track to deliver two exciting new companies
-
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
GSK and CureVac to develop next generation mRNA COVID-19 vaccines
-
GSK announces over $1M for local nonprofits to increase equity in STEM education and careers; Grants include funding for online science during pandemic
Our 10-year commitment to increase the number of women and Black and Latinx Philadelphia students entering careers in STEM
-
GSK announces gender and diversity aspirational targets to increase representation at senior levels
Aspirational targets to increase ethnically diverse senior leadership in the US and UK.
